Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage Top 10 Most Read Report
The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and competitors. Do you know why China-based companies traded on US exchanges are coming under pressure, what’s next for genetic medicine groups, and which new product launches…
Report library
Asco 2022 eBook
Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research,…
Q1 2022: Choppy Waters eBook
If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery…
Orphan Drug 2022 Report
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…
Genetic Medicine: The Next Generation
Huge investment in the first generation of genetic medicine led, by and large, to incredibly high valuations for companies, and before too long, some in the market began…
Orphan Drug 2022 Infographic
In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…
PD(L)anner - March 2022
The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing…
Vantage 2021 Review Report
Once again, our award-winning, independent editorial team provides thought-provoking insights into the business development decisions and financing deals that shaped the…
Vantage 2021 Review Infographic
Bringing you a snapshot of the critical themes from Evaluate Vantage’s 2021 in Review, this infographic touches on key business development decisions and financing deals…
JP Morgan 2022 Conference
Evaluate Vantage provided comprehensive coverage of the 40th Annual J.P. Morgan Health Care Conference, held virtually from 10 to 13 January. This article pack rounds…
PD(L)anner - December 2021
In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues,…
